Title
Development and Validation of Prediction Scores for Early Mortality at Transition to Dialysis.

Permalink
https://escholarship.org/uc/item/2d29v1st

Journal
Mayo Clinic proceedings, 93(9)

ISSN
0025-6196

Authors
Obi, Yoshitsugu
Nguyen, Danh V
Zhou, Hui
et al.

Publication Date
2018-09-01

DOI
10.1016/j.mayocp.2018.04.017

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
Development and Validation of Prediction Scores for Early Mortality at Transition to Dialysis

Yoshitsugu Obi, MD, PhD; Danh V. Nguyen, PhD; Hui Zhou, PhD; Melissa Soohoo, MPH; Lishi Zhang, MS; Yanjun Chen, MS; Elani Streja, MPH, PhD; John J. Sim, MD; Miklos Z. Molnar, MD, PhD; Connie M. Rhee, MD, MSc; Kevin C. Abbott, MD, MPH; Steven J. Jacobsen, MD, PhD; Csaba P. Kovacs, MD; and Kamyar Kalantar-Zadeh, MD, MPH, PhD

Abstract

Objective: To develop and validate a risk prediction model that would help individualize treatment and improve the shared decision-making process between clinicians and patients.

Patients and Methods: We developed a risk prediction tool for mortality during the first year of dialysis based on pre—end-stage renal disease characteristics in a cohort of 35,878 US veterans with incident end-stage renal disease who transitioned to dialysis treatment between October 1, 2007, and March 31, 2014 and then externally validated this tool among 4284 patients in the Kaiser Permanente Southern California (KPSC) health care system who transitioned to dialysis treatment between January 1, 2007, and September 30, 2015.

Results: To ensure model goodness of fit, 2 separate models were selected for patients whose last estimated glomerular filtration rate (eGFR) before dialysis initiation was less than 15 mL/min per 1.73 m² or 15 mL/min per 1.73 m² or higher. Model discrimination in the internal validation cohort of veterans resulted in C statistics of 0.71 (95% CI, 0.70-0.72) and 0.66 (95% CI, 0.65-0.67) among patients with eGFR lower than 15 mL/min per 1.73 m² and 15 mL/min per 1.73 m² or higher, respectively. In the KPSC external validation cohort, the developed risk score exhibited C statistics of 0.77 (95% CI, 0.74-0.79) in men and 0.74 (95% CI, 0.71-0.76) in women with eGFR lower than 15 mL/min per 1.73 m² and 0.71 (95% CI, 0.67-0.74) in men and 0.67 (95% CI, 0.62-0.72) in women with eGFR of 15 mL/min per 1.73 m² or higher.

Conclusion: A new risk prediction tool for mortality during the first year after transition to dialysis (available at www.DialysisScore.com) was developed in the large national Veterans Affairs cohort and validated with good performance in the racially, ethnically, and gender diverse KPSC cohort. This risk prediction tool will help identify high-risk populations and guide management strategies at the transition to dialysis.

© 2018 Mayo Foundation for Medical Education and Research

The number of incident cases of end-stage renal disease (ESRD) in the United States has risen over time and exceeded 120,000 in 2014.¹ There is substantial heterogeneity in the incident ESRD population in which some patients may die early after dialysis initiation while others may experience greater longevity with dialysis. Overall, mortality is exceptionally high during the first year of dialysis.¹

Plans for the initiation of maintenance dialysis therapy, including whether to initiate dialysis, integrate conservative care, or organize end-of-life support, are affected by various factors such as comorbid conditions, personal beliefs, and cultural perspectives.²,³ A risk prediction model to predict early mortality could help individualize treatment and support the shared decision-making process among clinicians, patients, and patients’ family members. For example, if a patient has high anticipated risk of mortality within 1 year of dialysis, conservative management with infrequent dialysis therapy could be a potential
option. Additionally, it may provide little or no benefit but rather harm in such a case to provide aggressive treatments for cancer or certain chronic conditions such as hypertension, atrial fibrillation, or hyperphosphatemia.

Several prediction models have been developed for patients among whom the decision to implement dialysis has been already made. However, most of the previous models utilized data obtained at the time of or after dialysis initiation despite the fact that the shared decision-making process regarding dialysis initiation would sometimes require several weeks. Other limitations of prior models include small sample sizes, restriction of study populations to those of elderly age, the use of less contemporary cohorts (before 2005), lack of information on race and/or ethnicity, and nonconsideration of readily available laboratory data such as serum albumin and/or estimated glomerular filtration rate (eGFR). Additionally, model performance was not externally validated in most cases.

The aim of this study was to develop, rigorously validate, and provide risk scores to predict mortality during the first year of dialysis (ie, months 3, 6, 9, and 12) based on pre-ESRD information among patients who would transition to dialysis.

**PATIENTS AND METHODS**

**Study Population and Data Source**

The Transition of Care in Chronic Kidney Disease study included 2 historical cohorts with incident ESRD: (1) 85,505 US veterans who transitioned to dialysis treatment from October 1, 2007, through March 31, 2014, and (2) 9700 KPSC patients transitioned to dialysis between 01/01/2007 and 09/30/2015.
patients who transitioned to dialysis within the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2007, through September 30, 2015, both derived from the United States Renal Data System (USRDS). In the current study, we excluded patients without data on eGFR during the 12 months before dialysis initiation, those without the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for renal disease, those with missing cause of ESRD, or unknown race/ethnicity (Figure 1, A). We further restricted patients in the KPSC cohort to those without missing data on the variables selected in the final model (Figure 1, B). Differences in characteristics between included vs excluded patients for each cohort are summarized in Supplemental Tables 1 and 2 (available online at http://www.mayoclinicproceedings.org). This study was approved by the institutional review boards of the Memphis, Tennessee, and Long Beach, California, Veterans Affairs (VA) Medical Centers and KPSC. The requirement for written informed consent was waived because of the large sample size, patient anonymity, and nonintrusive nature of the study.

Demographic Characteristics, Clinical Data, and Laboratory Measurements

Baseline patient characteristics were drawn from a composite of USRDS Patient and Medical Evidence files, Centers for Medicare and Medicaid Services (CMS) databases, and the respective administrative databases (ie, either the VA or KPSC). Cause of ESRD was categorized into 8 groups based on the ICD-9-CM diagnosis codes indicated in the Medical Evidence Report form CMS-2728 (Supplemental Table 3, available online at http://www.mayoclinicproceedings.org). We defined pre-ESRD comorbidity status by the ICD-9-CM diagnosis and surgical codes recorded in both CMS and administrative databases (Supplemental Table 4, available online at http://www.mayoclinicproceedings.org). Additionally, all patients with diabetes as the cause of ESRD were considered to have diabetes with complications. For comorbidities with 2 levels (ie, diabetes [with vs without complication], liver disease [mild vs moderate or severe], and cancer [nonmetastatic vs metastatic]), patients were considered to have only the more severe condition if they had both comorbidities. Ischemic heart disease included myocardial infarction.

All data on body mass index and laboratory tests were obtained before dialysis initiation. We calculated eGFR using the Chronic Kidney Disease Epidemiology Collaboration formula. The last measurement of each variable before ESRD transition was used in this study.

Statistical Analyses

Differences between groups were compared by standardized differences because of the large sample size of this study. Differences in patient characteristics between 2 groups were compared by standardized difference, of which 0.8, 0.5, and 0.2 in absolute value were considered large, medium, and small differences, respectively.

Prediction models for mortality during the first year of dialysis were developed on the basis of survival data up to 14 months after transition to dialysis using Cox proportional hazards models. Follow-up started at dialysis initiation and continued until death or the date of final follow-up assessment (September 2, 2014). Information on date of censoring events was obtained from the records of the CMS, USRDS, and respective administrative database. As candidate predictors, we a priori selected clinically relevant variables less likely to be intentionally modified (Table 1) and excluded medications and easily modifiable variables (ie, hemoglobin, potassium, calcium, phosphorus, intact parathyroid hormone, bicarbonate, ferritin, and lipids). The proportions of missing data were approximately 3% for body mass index, serum sodium, and serum urea nitrogen and approximately 10% for white blood cell, serum albumin, and serum alkaline phosphatase. Missing data in the VA cohort were imputed by their mean values.

The VA cohort was randomly divided into a two-thirds development set (n = 24,030) and a one-third internal validation set (n = 11,848). Final models with reduced number of predictors were obtained in the development data set using backward selection based on Akaike information criterion. To address potential model overfitting (optimism), we estimated a linear shrinkage factor (γ) using 100 bootstrap samples and adjusted the risk score by the
| Candidate predictors                  | Total cohort (N=35,878) | Last eGFR (mL/min/1.73 m²) | Standardized difference<sup>3</sup> |
|--------------------------------------|-------------------------|----------------------------|---------------------------------|
|                                      |                         | <15 (n=22,605 [63%])      | ≥15 (n=13,273 [37%])          |
|                                      |                         | (77)                      | (99)                           |
| Age (y) 0                            | 69.4±1.1                |                            |                                |
| Male 0                               | 35,215 (98)             |                            |                                |
| Race 0                               |                         |                            |                                |
| White 0                              | 24,344 (68)             | 14.123 (62)                | 10.221 (77)                    | −0.32 |
| Black 0                              | 9913 (28)               | 7323 (32)                  | 2590 (20)                      | 0.30  |
| Native American 0                    | 204 (0.6)               | 145 (0.6)                  | 59 (0.4)                       | 0.03  |
| Asian 0                              | 196 (0.5)               | 135 (0.6)                  | 61 (0.5)                       | 0.02  |
| Other 0                              | 1221 (3)                | 879 (4)                    | 342 (3)                        | 0.07  |
| Hispanic ethnicity 0                 | 2474 (7)                | 1796 (8)                   | 678 (5)                        | 0.12  |
| Cause of ESRD 0                      |                         |                            |                                |
| Diabetes 0                           | 17,182 (48)             | 11,098 (49)                | 6084 (46)                      | 0.07  |
| Hypertension/large-vessel disease 0  | 10,847 (30)             | 6791 (30)                  | 4056 (31)                      | −0.01 |
| Primary glomerulonephritis 0         | 1766 (5)                | 1360 (6)                   | 406 (3)                        | 0.14  |
| Interstitial nephritis/pyelonephritis| 919 (3)                 | 588 (3)                    | 331 (2)                        | 0.01  |
| Neoplasms/tumors 0                  | 886 (2)                 | 478 (2)                    | 408 (3)                        | −0.06 |
| Cystic/hereditary/congenital diseases| 582 (2)                 | 468 (2)                    | 114 (9)                        | 0.10  |
| Secondary glomerulonephritis/vasculitis| 295 (0.8)              | 189 (0.8)                  | 106 (0.8)                      | 0.00  |
| Comorbidities (ICD-9-CM) 0           |                         |                            |                                |
| Renal disease 0                      | 35,878 (100)            | 22,605 (100)               | 13,273 (100)                   | 0.00  |
| Hypertension 0                       | 35,231 (98)             | 22,111 (98)                | 13,104 (99)                    | 0.07  |
| Hyperlipidemia 0                     | 29,416 (82)             | 17,852 (79)                | 11,564 (87)                    | −0.22 |
| Anemia 0                            | 26,481 (74)             | 16,404 (73)                | 10,077 (76)                    | −0.08 |
| Diabetes without complications 0     | 6577 (18)               | 4019 (18)                  | 2558 (19)                      | −0.04 |
| Diabetes with complications 0        | 18,980 (53)             | 11,694 (52)                | 7286 (55)                      | −0.06 |
| Ischemic heart disease 0             | 21,234 (59)             | 11,527 (51)                | 9707 (73)                      | −0.47 |
| Myocardial infarction 0              | 9397 (26)               | 4491 (20)                  | 4906 (37)                      | −0.39 |
| Congestive heart failure 0           | 19,870 (55)             | 10,462 (46)                | 9408 (71)                      | −0.52 |
| Atrial fibrillation 0                | 5733 (16)               | 2530 (11)                  | 3203 (24)                      | −0.34 |
| Peripheral vascular disease 0        | 13,773 (38)             | 7291 (32)                  | 6482 (49)                      | −0.34 |
| Cerebrovascular disease 0            | 11,197 (31)             | 6088 (27)                  | 5109 (38)                      | −0.25 |
| Depression 0                         | 8980 (25)               | 5615 (25)                  | 3365 (25)                      | 0.01  |
| Dementia 0                           | 837 (2)                 | 437 (2)                    | 400 (3)                        | 0.07  |
| Chronic pulmonary disease 0          | 14,973 (42)             | 7653 (34)                  | 7320 (55)                      | −0.44 |
| Mild liver disease 0                 | 3128 (9)                | 1888 (8)                   | 1240 (9)                       | −0.03 |
| Moderate or severe liver disease 0   | 776 (2)                 | 330 (1)                    | 446 (3)                        | −0.12 |
| Nonmetastatic cancer 0               | 7510 (21)               | 4367 (19)                  | 3143 (24)                      | −0.11 |
| Metastatic carcinoma 0               | 806 (2)                 | 379 (2)                    | 427 (3)                        | −0.10 |
| Peptic ulcer disease 0               | 2363 (7)                | 1199 (5)                   | 1164 (9)                       | −0.14 |
| Connective tissue disease/rheumatic disease| 1345 (4)              | 677 (3)                    | 668 (5)                        | −0.10 |
| Paraplegia/hemiplegia 0              | 1116 (3)                | 592 (3)                    | 524 (4)                        | −0.07 |
| HIV/AIDS 0                           | 361 (1)                 | 267 (1)                    | 94 (0.7)                       | 0.05  |
| Body mass index (kg/m²) 0            | 29.9±6.7                | 29.7±6.5                   | 30.1±6.9                       | −0.07 |
| Last eGFR (mL/min/1.73 m²) 0         | 12.4 (8.6-18.6)         | 9.5 (7.2-11.9)             | 21.9 (17.6-30.7)               | −2.58 |
| Laboratory tests                     |                         |                            |                                |
| White blood cells (×10³/μL) 0        | 7.3 (5.9-9.0)           | 7.3 (5.9-9.1)              | 7.2 (5.8-8.9)                  | 0.05  |
| Serum sodium (mEq/L) 2               | 139.1±3.7               | 138.9±3.8                  | 139.3±3.5                     | −0.10 |
| Serum albumin (g/dL) 9               | 3.4±0.6                 | 3.3±0.6                    | 3.5±0.6                       | −0.21 |

Continued on next page
Laboratory tests, continued

Differences in patient characteristics between 2 groups were compared by standardized difference, of which 0.8, 0.5, and 0.2 in absolute value were considered large.

SI conversion factors: To convert white blood cell values to \( \times 10^9/\text{L} \), multiply by 0.001; to convert sodium values to mmol/L, multiply by 1.0; to convert albumin values to g/dL, multiply by 10; to convert urea nitrogen values to mmol/L, multiply by 0.357; to convert alkaline phosphatase values to \( \text{IU}/\text{L} \), multiply by 0.001; and to convert calcium values to mmol/L, multiply by 0.025.

| Candidate predictors | Missing frequency (%) | Total cohort (N=35,878) | Last eGFR (mL/min/1.73 m²) | Standardized difference |
|---------------------|-----------------------|-------------------------|---------------------------|-------------------------|
|                     |                       | <15 (n=22,605 [63%])    | ≥15 (n=13,273 [37%])     |                         |
| Serum urea nitrogen (mg/dL) | 4 | 65±29 | 75±27 | 48±23 | 1.09 |
| Serum alkaline phosphatase (IU/L) | 11 | 82 (64-108) | 80 (63-105) | 86 (67-115) | −0.19 |

* eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; HIV = human immunodeficiency virus; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; IQR = interquartile range.

** Values are presented as mean ± SD, median (IQR), or No. (percentage). Percentages may not total 100 because of rounding.

** SI conversion factors: To convert white blood cell values to \( \times 10^9/\text{L} \), multiply by 0.001; to convert sodium values to mmol/L, multiply by 1.0; to convert albumin values to g/dL, multiply by 10; to convert urea nitrogen values to mmol/L, multiply by 0.357; to convert alkaline phosphatase values to \( \text{IU}/\text{L} \), multiply by 0.001; and to convert calcium values to mmol/L, multiply by 0.025.

** Differences in patient characteristics between 2 groups were compared by standardized difference, of which 0.8, 0.5, and 0.2 in absolute value were considered large, medium, and small differences, respectively.

...shrinkage factor. Overfitting, particularly in small data sets, results in regression coefficients being overestimated (overfitted) for prediction. Thus, a shrinkage factor (0 ≤ γ ≤ 1) is estimated and applied to the risk score to shrink the regression coefficients towards zero so that predictions will more likely show better calibration on new patients (ie, validation data). Furthermore, our study has 2 additional protections against overfitting, ie, internal and external validation cohorts.

Model calibration was assessed by calibration plots and a group-based goodness-of-fit test for survival model.27 In both the internal and external validation data sets, model predictive discrimination was assessed using the index of concordance, or C statistic.25

The final prediction models based on the shrunken prognostic score (PS) can be used to estimate the predicted probabilities of all-cause death at a given time \( t \) (month). That is, the shrunken PS* that will be used to predict the outcomes of new/future patients will be PS* = γ × β, where β is the collection of estimated coefficients in the final prediction model. The predicted survival at time \( t \) for a new patient can be obtained as \( S_0(t)^{exp(PS*)} \), where \( S_0(t) \) is the baseline survival estimate from the final model. Kaplan-Meier survival estimates were compared with predicted mortality at months 3, 6, 9, and 12 across 5 risk score categories based on cutoff points at 5th, 35th, 65th, and 95th percentiles in respective eGFR groups of the internal validation cohort. However, predicted survival rates and their 95% CIs were not provided for the external validation cohort due to data confidentiality because it required merging of the VA and KPSC data at the individual level.

Analyses were performed in SAS version 9.3 PROC PHREG (SAS Institute) and R version 3.12 (R Project for Statistical Computing) using libraries RMS and SURVIVAL.

**RESULTS**

**Baseline Characteristics of the VA Cohort**

The 35,878 patients in the VA cohort had a mean (SD) age of 69.4±11.1 years, 35,215 (98%) were male, 24,344 (68%) were white, 2474 (7%) were Hispanic, and 17,182 (48%) had diabetes as the cause of their ESRD (Table 1). The last eGFR before dialysis initiation was 12.4 mL/min per 1.73 m² (interquartile range [IQR], 8.6-18.6 mL/min per 1.73 m²), and the prevalence of low and high eGFR (ie, <15 or ≥15 mL/min per 1.73 m²) were 63% (n=22,605) and 37% (n=13,273), respectively. When compared with patients with low eGFR, those with high eGFR were older, more likely to be white, and more likely to have a history of hyperlipidemia, cardiovascular disease, and chronic pulmonary disease (absolute standardized difference, >0.2). There were no meaningful differences between the development and internal validation data sets (Supplemental Table 5, available online at http://www.mayoclinicproceedings.org). The time from the last eGFR measurement to dialysis initiation was 24 days (IQR, 3-109 days). The prevalence of hemodialysis and peritoneal dialysis as the initial dialysis modality was 94% (11,162) and 5% (579), respectively.
respectively, and dialysis modality was uncertain among 107 patients (1%). There were a total of 9813 deaths (4525 and 5288 deaths among patients with low and high eGFR, respectively) during the median follow-up of 14 months (IQR, 9-14 months). Six-month and 1-year mortality rates were 10% and 18% among patients with low eGFR, respectively, and 25% and 37% among patients with high eGFR, respectively.

**Development of the Prediction Score**

A single prediction score resulted in poor model fit (P<.001 for goodness-of-fit test). We then evaluated model fit by stratifying patients according to age, race, diabetes as the cause of ESRD, initial dialysis modality, and time from the last eGFR measurement to dialysis initiation, and only stratification based on the last eGFR resulted in significant improvement (P>.1 for goodness-of-fit test) (Supplemental Table 6, available online at http://www.mayoclinicproceedings.org). This led to the development of 2 separate prediction scores for patients stratified by low and high eGFR. The final early mortality prediction model coefficients are presented in Table 2. The performances of our reduced/simplified models as quantified by C statistics were practically the same as the full models (data not shown).

Supplemental Figure 1, A and B (available online at http://www.mayoclinicproceedings.org) shows the predicted probability of 1-year mortality after transitioning to dialysis as a function of risk score (ie, risk plots). Calibration plots comparing observed vs predicted 1-year survival graphically exhibited consistent results (Supplemental Figure 2, A and B, available online at http://www.mayoclinicproceedings.org). We also compared Kaplan-Meier estimates and predicted survival at months 3, 6, 9, and 12 after dialysis initiation across 5 categories with cutoff points at 5th, 35th, 65th, and 95th percentiles of risk score in respective eGFR groups (Figure 2, A and B). Predicted survival was slightly lower than actual in the lowest-risk group but was otherwise consistent (well calibrated) with the observed survival.

**Internal Validation Within the VA Cohort**

The performance of the prediction score was tested in the internal validation data set of 11,848 veterans. The model discrimination was acceptable among patients with low eGFR, with a C statistic of 0.71 (95% CI, 0.70-0.72). The prediction model showed a C statistic of 0.66 (95% CI, 0.65-0.67) among those with high eGFR. Subgroup analyses including initial dialysis modality (ie, hemodialysis vs peritoneal dialysis) showed consistent C statistics except for patients aged 65 years or older, in whom C statistics were 0.66 (95% CI, 0.65-0.68) and 0.63 (95% CI, 0.61-0.64) for those with low and high eGFR, respectively (Table 3). Risk plots are shown in Supplemental Figure 1, C and D.

The group-based goodness-of-fit tests showed no significant difference between observed and predicted 1-year mortality after transitioning to dialysis in both the low and high eGFR groups (overall P>.1) (Supplemental Table 6). Calibration plots exhibited consistent results (Supplemental Figure 2, C and D). Predicted vs observed Kaplan-Meier estimates were also consistent, as were those in the development cohort (Figure 2, C and D).

**External Validation**

Compared with the VA cohort (n = 35,8780), the KPSC cohort (n = 4284) was younger (65±14 years vs 69±11 years) and included more women (43% [1842] vs 2% [663]), more Asians (11% [487] vs 0.5% [196]), and more Hispanics (30% [1298] vs 7% [2474]) (Supplemental Table 7, available online at http://www.mayoclinicproceedings.org). The last eGFR before dialysis initiation in the KPSC cohort was 10.5 mL/min per 1.73 m² (IQR, 7.7-14.1 mL/min per 1.73 m²), and the prevalence of low and high eGFR (<15 or ≥15 mL/min per 1.73 m²) was 79% (3363) and 21% (921), respectively. Time from the last eGFR measurement to dialysis initiation was 11 days (IQR, 5-25 days), and the prevalence of hemodialysis and peritoneal dialysis as the initial dialysis modality was 87% (3727) and 13% (557), respectively. Supplemental Table 8 summarizes data on predictors in the final model stratifying KPSC patients by sex and last eGFR before dialysis initiation. There were a total of 824 deaths (552 and 272 deaths among patients with low and high eGFR, respectively) during the median follow-up time of 14 months (IQR,
### TABLE 2. Cox Regression Model for Predicting Mortality Among Patients With Low and High eGFR at the Last Measurement Before Dialysis Initiation

| Variable                                      | Parameter | HR (95% CI) | P value | Parameter | HR (95% CI) | P value |
|-----------------------------------------------|-----------|-------------|---------|-----------|-------------|---------|
| **Age (per year)**                           | 0.0311    | 1.03 (1.03-1.04) | <.001  | 0.0343    | 1.03 (1.03-1.04) | <.001  |
| **Race**                                      |           |             |         |           |             |         |
| White                                         | 0.4019    | 0.67 (0.61-0.73) | <.001  | -0.2178   | 0.80 (0.73-0.89) | <.001  |
| Black                                         | -0.6334   | 0.53 (0.29-0.96) | .04    | -0.8342   | 0.43 (0.23-0.81) | .009   |
| Asian                                         | -0.4859   | 0.61 (0.36-1.04) | .07    | -0.6384   | 0.53 (0.27-1.02) | .06    |
| Native American                               | -0.3692   | 0.69 (0.55-0.87) | .002   | -0.2437   | 0.78 (0.60-1.02) | .07    |
| Other                                         | -0.2926   | 0.75 (0.64-0.87) | <.001  | -0.2547   | 0.78 (0.64-0.93) | .007   |
| **Hispanic ethnicity**                        |           |             |         |           |             |         |
| Hispanic                                      | -0.2926   | 0.75 (0.64-0.87) | <.001  | -0.2547   | 0.78 (0.64-0.93) | .007   |
| **Cause of ESRD**                             |           |             |         |           |             |         |
| Diabetes                                      | 0.3607    | 1.43 (1.18-1.74) | <.001  | 0.3493    | 1.42 (1.12-1.79) | .003   |
| Hypertension/large-vessel disease             | 0.4261    | 1.53 (1.26-1.87) | <.001  | 0.3428    | 1.41 (1.11-1.78) | .004   |
| Primary glomerulonephritis                    | 0.5392    | 1.71 (1.30-2.26) | <.001  | 0.5632    | 1.76 (1.30-2.37) | <.001  |
| Intestinal nephritis/peyelonephritis          | 0.8410    | 2.32 (1.78-3.01) | <.001  | 0.4618    | 1.59 (1.18-2.13) | .002   |
| Neoplasms/tumors                              | -0.0997   | 0.91 (0.59-1.40) | .66    | -0.5306   | 0.59 (0.32-1.08) | .09    |
| Cystic/hereditary/congenital diseases         | 0.3890    | 1.48 (0.97-2.25) | .07    | 0.3876    | 1.47 (0.95-2.27) | .08    |
| Secondary glomerulonephritis/vasculitis       | 0.7526    | 2.12 (1.71-2.63) | <.001  | 0.4874    | 1.63 (1.28-2.07) | <.001  |
| **Miscellaneous conditions**                 |           |             |         |           |             |         |
| Hyperlipidemia                                | -0.1485   | 0.86 (0.78-0.95) | .002   | -0.1886   | 0.83 (0.74-0.92) | .001   |
| Diabetes without complications                | -0.1485   | 0.86 (0.78-0.95) | .002   | -0.1886   | 0.83 (0.74-0.92) | .001   |
| Ischemic heart disease                        | -0.1485   | 0.86 (0.78-0.95) | .002   | -0.1886   | 0.83 (0.74-0.92) | .001   |
| Myocardial infarction                         | 0.1555    | 1.17 (1.07-1.27) | <.001  | 0.1191    | 1.13 (1.04-1.22) | .004   |
| Congestive heart failure                      | 0.2273    | 1.25 (1.16-1.36) | <.001  | 0.2353    | 1.27 (1.15-1.39) | <.001  |
| Atrial fibrillation                           | 0.2013    | 1.22 (1.11-1.35) | <.001  | 0.1835    | 1.20 (1.11-1.30) | <.001  |
| Peripheral vascular disease                   | 0.1251    | 1.13 (1.05-1.23) | .002   | Not selected |          |        |
| Cerebrovascular disease                       | 0.1727    | 1.19 (1.10-1.29) | <.001  | 0.1035    | 1.11 (1.03-1.19) | .004   |
| Dementia                                      | 0.2426    | 1.53 (1.27-1.85) | <.001  | Not selected |          |        |
| Chronic pulmonary disease                     | 0.1796    | 1.20 (1.11-1.29) | <.001  | 0.1482    | 1.16 (1.08-1.25) | <.001  |
| Moderate or severe liver disease              | 0.7509    | 2.12 (1.70-2.64) | <.001  | 0.5212    | 1.68 (1.44-1.97) | <.001  |
| Metastatic carcinoma                          | 0.7012    | 2.02 (1.68-2.43) | <.001  | 0.2675    | 1.31 (1.12-1.53) | <.001  |
| **Body mass index (per kg/m²)**               | -0.0304   | 0.97 (0.96-0.98) | <.001  | -0.0233   | 0.98 (0.97-0.98) | <.001  |
| Last eGFR (per mL/min/1.73 m²)                | 0.0308    | 1.03 (1.02-1.05) | <.001  | 0.0163    | 1.02 (1.01-1.02) | <.001  |
| **Laboratory tests**                          |           |             |         |           |             |         |
| White blood cells (per x 10³/μL)             | 0.0269    | 1.03 (1.02-1.04) | <.001  | Not selected |          |        |
| Serum albumin (per g/dL)                      | -0.4381   | 0.65 (0.61-0.68) | <.001  | -0.2610   | 0.77 (0.73-0.82) | <.001  |
| Serum urea nitrogen (per mg/dL)               | 0.0025    | 1.00 (1.00-1.00) | .001   | 0.0057    | 1.01 (1.00-1.01) | <.001  |
| Serum sodium (per mEq/L)                     | -0.0327   | 0.97 (0.96-0.98) | <.001  | -0.0331   | 0.97 (0.96-0.98) | <.001  |
| Serum alkaline phosphatase (per IU/L)         | 0.0010    | 1.00 (1.00-1.00) | <.001  | 0.0012    | 1.00 (1.00-1.00) | <.001  |

*eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; HR = hazard ratio.

Model parameter estimate before application of shrinkage factor (ie, 0.970 and 0.965 for low and high eGFR groups, respectively). Estimated 1-year survival probabilities can be obtained as: \( S(t) = S_0 \exp(PS*t) \), where PS = \( \gamma \times LP \), \( \gamma \) is the shrinkage factor, LP is the linear predictor using the given parameter estimates, and \( S_0(t) \) is the baseline survival estimate from the final model. \( S_0(t) \) at months 3, 6, 9, and 12 were 0.9722, 0.9446, 0.9234, and 0.9011 for patients with last eGFR <15 mL/min/1.73 m², respectively, and 0.9313, 0.8790, 0.8369, and 0.7994 for patients with last eGFR ≥15 mL/min/1.73 m², respectively.

Last available value during 1 year before dialysis initiation.
FIGURE 2. Observed survival curves during the first year of dialysis and predicted survival at months 3, 6, 9, and 12 across 5 risk score categories in patients with last estimated glomerular filtration rate (eGFR) before initiation of dialysis of less than 15 mL/min per 1.73 m² or 15 mL/min per 1.73 m² or greater in the development Veterans Affairs (VA) cohort (A and B), the internal validation VA cohort (C and D), and the external validation Kaiser Permanente Southern California (KPSC) cohort (E and F), respectively. Survival curves (solid lines) were based on Kaplan-Meier (KM) estimates. Points and bars represent means and 95% CIs of predicted survival for the risk score categories. Cutoff points were selected at 5th, 35th, 65th, and 95th percentiles in respective eGFR groups of the internal validation cohort and were consistent across cohorts. Predicted survival rates and their 95% CIs were not provided for the external validation cohort due to data confidentiality because it requires merging of the VA and KPSC data at the individual level.
and F) show the same consistent ordering of survival and risk score percentile (ie, high risk score, high mortality), and the prediction score showed similar or even better discrimination in the KPSC cohort than in the VA cohort; C statistics were 0.77 (95% CI, 0.74-0.79) and 0.74 (95% CI, 0.71-0.76) among men and women with low eGFR, respectively, and 0.71 (95% CI, 0.67-0.74) and 0.67 (95% CI, 0.62-0.72) among men and women with high eGFR, respectively.

**DISCUSSION**

In this study, we developed a prediction tool for mortality during the first year of dialysis based on pre-ESRD data in a large contemporary national cohort of US veterans. Although the VA cohort has inherently unique characteristics compared with other populations, these new risk scores appeared generalizable given that these were externally validated in the racially, ethnically, and gender diverse KPSC cohort with reasonable discrimination in most studies groups. In order to facilitate practical implementation, we have created an online risk score calculator at www.DialysisScore.com that provides the predicted risk of mortality at months 3, 6, 9, and 12 after dialysis initiation.

The discriminatory performance of our risk score may be improved by adding other factors such as socioeconomic status, medication adherence, and timing of referral to nephrologists. In particular, physical and cognitive function may play an important role in predicting outcomes among elderly patients, in whom our risk score showed C statistics of less than 0.7. Indeed, geriatric syndromes such as cognitive impairment and frailty are prevalent in the dialysis population, and the decline in cognitive and physical function has been shown to accelerate after dialysis initiation, especially among elderly patients. These variables are difficult to capture because trained personnel and careful consideration are necessary for their evaluation, but comprehensive risk models accounting for additional measures specific to the elderly population may help predict mortality more precisely.

Several previous prediction models focused on the elderly population given the differences in clinical consequences (eg, high mortality and hospitalization rates) and patient
that in previous studies,\(^7\) and these heterogeneous conditions may explain why model fit was improved by stratification according to last eGFR and why we observed lower C statistics among patients with high eGFR. The patterns of mortality during the first year of dialysis have been reported to differ by age and treatment modality.\(^1\) For patients undergoing hemodialysis, mortality is especially high during the first several months, and this early mortality is more remarkable among older patients. In contrast, patients undergoing peritoneal dialysis have relatively constant mortality over the course of the year. Nevertheless, a previous study reported similar outcomes between dialysis modalities when accounting for patient characteristics,\(^38\) and our risk scores had consistent C statistics across subgroups of age and treatment modality (Table 3). Predicted survival was also concordant with observed survival across risk groups and time points except for month 6 in the highest risk score group (ie, \(\geq 95\text{th percentile of risk score}\)) among patients with a last eGFR of 15 mL/min per 1.73 m\(^2\) or higher (Figure 2). This group was the oldest population, and their overestimated survival may be explained by the early mortality phenomena among the elderly.

Our study results should be interpreted with several potential limitations in mind. First, the model performance may depend on the accuracy of data on comorbid conditions. We used specific ICD-9-CM codes in the CMS and administrative databases but were not able to confirm their accuracy. However, our prediction model was externally validated in the KPSC cohort where clinical practice is different from that of the VA, suggesting little impact of this potential bias. Furthermore, by using diagnostic codes to identify the presence of comorbid conditions, our score lends itself to automated implementation in electronic medical records. Second, although prediction performances (C statistics) were similar for the development and internal validation for the VA cohort as well as the external KPSC cohort, overall calibration was better for the interval validation cohort (Supplemental Figure 2) as expected because of the survival differences in the KPSC and VA cohorts. Future model refinements may include a mixture of patient cohorts more representative of the general dialysis population. Third, timing to use this risk score would also affect the model performance because values in selected variables change over time. Although C statistics were consistent between veterans with different time periods between the last eGFR measurement and dialysis initiation (ie, \(<6\) vs \(\geq6\) months) (Table 3), our model showed greater discrimination in the lower eGFR groups and the KPSC cohort, in whom the lag period was shorter than that of their counterparts. Fourth, our cohort consisted mostly of whites and blacks. Although the KPSC cohort included 11% Asians, predicted mortality should be interpreted with caution in races other than whites or blacks before being validated in a specific race. Lastly, we did not account for vascular access. However, several studies have found that the mortality risk associated with vascular access may largely be accounted for by patient characteristics.\(^39,40\)

CONCLUSION
A new prediction tool for mortality during the first year of dialysis was developed and externally validated among incident dialysis patients in the United States. This tool is available at our website www.DialysisScore.com, which allows clinicians, patients, and patient family members to obtain the predicted mortality at months 3, 6, 9, and 12 after dialysis initiation. Our new tool could help improve nephrology care and may facilitate shared decision making for individualized preparation for dialysis initiation in late stages of chronic kidney disease.
ACKNOWLEDGMENTS

Drs Streja, Kovesdy, and Kalantar-Zadeh are employees of the US Department of Veterans Affairs. The interpretation and reporting of these data are the responsibility of the authors and should in no way be considered as official policy or interpretation of the US Department of Veterans Affairs or the US government. Funders/sponsors had no role in analysis and interpretation of the data, preparation, review, or approval of the submitted manuscript, and decision to submit the manuscript for publication.

SUPPLEMENTAL ONLINE MATERIAL

Supplemental material can be found online at http://www.mayoclinicproceedings.org. Supplemental material attached to journal articles has not been edited, and the authors take responsibility for the accuracy of all data.

Abbreviations and Acronyms: CMS = Centers for Medicare and Medicaid Services; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; ICD-9-CM = International Classification of Diseases; Ninth Revision = Clinical Modification; IQR = interquartile range; KPSC = Kaiser Permanente Southern California; PS = prognostic score; USRDS = United States Renal Data System; VA = Veterans Affairs

Affiliations (Continued from the first page of this article.): Kaiser Permanente Southern California, Pasadena, CA (H.Z., J.J.S., S.J.); Institute for Clinical and Translational Science, University of California, Irvine, CA (L.Z., Y.C.); Nephrology Section, Tibo Rubin Veterans Affairs Medical Center, Long Beach, CA (E.S., K.K.-Z.); Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN (M.Z.M., C.P.K.); Division of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN (M.Z.M.); Division of Transplant Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN (M.Z.M.); Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary (M.Z.M.); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (K.C.A.); Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, TN (C.P.K.); and Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA (K.K.-Z.).

Grant Support: This work was supported in part by grant U01-DK1012163 from the National Institutes of Health (S.J., K.K.-Z., C.P.K.) and by resources from the US Department of Veterans Affairs. The data reported here have been supplied in part by the US Renal Data System. Support for the Department of Veterans Affairs/Centers for Medicare and Medicaid Services data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, and Veterans Affairs Information Resource Center (project numbers SDR 02-237 and 98-004). Dr Kalantar-Zadeh is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K24-DK091419 as well as philanthropic grants from Mr Harold Simmons, Mr Louis Chang, and Dr Joseph Lee. Dr Obi is supported by the Uehara Memorial Foundation Research Fellowship. Dr Rhee is supported by grants K23-DK102903 and R03-DK114642 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Streja is supported by Department of Veterans Affairs grant K2-CX001266-001. Dr Nguyen is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01-DK092232.

Potential Competing Interests: Dr Kalantar-Zadeh has received honoraria and/or support from Abbott, AbbieVe Inc, Alexion Pharmaceuticals, Inc, Amgen Inc, the American Society of Nephrology, AstraZeneca, Aveo Pharmaceuticals, Inc, Chugai Pharmaceutical Co, Inc, DaVita Inc, Fresenius Medical Care, Genetech, Inc, Haymarket Media Group, Hospira, Fresenius Kabi AG, Keryx Biopharmaceuticals, Inc, the National Institutes of Health, the National Kidney Foundation, Relypsa, Inc, Resverlogix Corp, Sanofi, Shire, Vifor Pharma, and ZS-Pharma, Inc, for work not related to this article. Dr Molnar has received consultation fees from Merck & Co, Inc, for work not related to this article. Dr Obi has received honoraria and/or support from Chugai Pharmaceutical Co and Ono Pharmaceutical Co, Inc, for work not related to this article. The other authors report no potential competing interests.

Data Previously Presented: This study was presented in part at Kidney Week 2017 in New Orleans, LA.

Correspondence: Address to Kamyar Kalantar-Zadeh, MD, PhD, MPH, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California, Irvine, 333 City Blvd W, City Tower, Ste 400, Orange, CA 92868 (kz@uci.edu).

REFERENCES

1. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States [published correction appears in Am J Kidney Dis. 2017;69(5):712]. Am J Kidney Dis. 2017; 69(3 suppl 1):A7-A8.
2. Coughoud C, Hemmelgarn B, Katankon P, German MJ, Moranne O, Davison SN. Supportive care: time to change our prognostic tools and their use in CKD. Clin J Am Soc Nephrol. 2016;11(10):1892-1901.
3. Brown EA, Bekker HL, Davison SN, Koffman J, Scheil JO. Supportive care: communication strategies to improve cultural competence in shared decision making. Clin J Am Soc Nephrol. 2016;11(10):1902-1908.
4. Rhee CM, Ghaemreza-Ghajar M, Obi Y, Kalantar-Zadeh K. Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management. Perminvest. Med. 2017;59(2):188-196.
5. Obi Y, Streja E, Rhee CM, et al. Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: a cohort study. Am J Kidney Dis. 2016;68(2):252-265.
RISK SCORE AT TRANSITION TO DIALYSIS

6. Bolasco P, Cupisti A, Locatelli F, Caria S, Kalantar-Zadeh K. Dietary management of incremental transition to dialysis therapy: once-weekly hemodialysis combined with low-protein diet [published correction appears in J Ren Nutr. 2017;27(1):74]. J Ren Nutr. 2016;26(6):352-359.

7. Wick JP, Turin TC, Paris PD, et al. A clinical risk prediction tool for 6-month mortality after dialysis initiation among older adults. Am J Kidney Dis. 2017;69(5):568-575.

8. Foley RN, Parfrey PS, Hefferton D, Singh J, Simms A, Barrett BJ. Advance prediction of early death in patients starting maintenance dialysis. Am J Kidney Dis. 1994;23(6):836-845.

9. Barrett BJ, Parfrey PS, Morgan J, et al. Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis. 1997;29(2):214-222.

10. Thamer M, Kaufman JS, Zhang Y, Zhang Q, Cotter DJ, Bang H. Predicting early death among elderly dialysis patients: development and validation of a risk score to assist shared decision making for dialysis initiation. Am J Kidney Dis. 2015;66(6):1024-1032.

11. Couchoud CG, Beuscart JB, Aldigier JC, Brunet PJ, Moranne O, et al; French Renal Epidemiology and Information Network (REIN) Registry. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant. 2009;24(5):1553-1561.

12. Wagner M, Ansell D, Kent DM, et al. Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis. 2015;65(5):894-902.

13. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ. An nonparametric approach for baseline covariate adjustment for two-group comparative studies. Biometrics. 2008;64(4):1110-1116.

14. Harrell F. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. 2nd ed. Basel, Switzerland: Springer International Publishing; 2015.

15. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.

16. Steyerberg EW, Eijkemaans MJC, Habbema JDF. Application of shrinkage techniques in logistic regression analysis: a case study. Stat Med. 2001;55(1):76-88.

17. Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res. 2016;25(4):1692-1706.

18. Nicholas SB, Kalantar-Zadeh K, Norms KC. Socioeconomic disparities in chronic kidney disease. Adv Chronic Kidney Dis. 2015;22(1):15-16.

19. Gosmanova EO, Molnar MZ, Ankali A, et al. Impact of non-adherence on renal and cardiovascular outcomes in US veterans. Am J Nephrol. 2015;42(2):151-157.

20. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis. 2003;41(2):310-318.

21. Winkelmaier WC, Owen WF Jr, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. Am J Soc Nephrol. 2003;41(2):486-492.

22. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.

23. Schacht A, Bogarti K, Bluhmki E, Lesaffre E. A new nonparametric approach for baseline covariate adjustment for two-group comparative studies. Biometrics. 2008;64(4):1110-1116.

24. Kalantar-Zadeh K, Kovesdy CP, Streja E, et al. Transition of care primarily due to patient factors. J Am Soc Nephrol. 2017;28(2):645-652.

25. Quinn RR, Oliver MJ, Devoe D, et al. The effect of predialysis fistula attempt on risk of all-cause and access-related death. J Am Soc Nephrol. 2017;28(2):613-620.

Mayo Clin Proc. ■ September 2018;93(9):1224-1235 ■ https://doi.org/10.1016/j.mayocp.2018.04.017
www.mayoclinicproceedings.org